

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON BUSINESS DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group’s subsidiaries Hebei Guangxiang Pharmaceutical Co., Ltd. and Hebei Guolong Pharmaceutical Co., Ltd have been recently recognized as provincial level “specialized and new” small and medium size enterprise (「專精特新」中小企業) in Hebei Province by Hebei Provincial Department of Industry and Information Technology (河北省工業和信息化廳) (the “Department”).

According to the relevant administrative measures, the Department will integrate relevant public service resources and give priority to recognised “specialized and new” small and medium size enterprise in provision of key fostering supports to enterprises under the same conditions, including measures such as recommendation on having benefits under policies of relevant national and provincial specific funding support and under relevant preferential policies of promoting development of small and medium-sized enterprises, and recommendations on assess to domestic multi-level capital market.

In addition, the Board is also pleased to announce that recently, Shijiazhuang No. 4 Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Group, has been recognized by the National Development and Reform Commission as the second batch of development pilot enterprise of advanced manufacturing industry and modern service industry integration (先進製造業和現代服務業融合) (the “two-industry integration”), being one of the only two enterprises in Hebei Province, and will play a demonstrative role as the pilot of the two-industry integration. Hebei Guangxiang Pharmaceutical Co., Ltd. has been recognized by the Hebei Provincial Development and Reform Commission as an Hebei Province Enterprise Technology Center (河北省企業技術中心), and has also been confirmed by the Hebei Provincial Department of Science and Technology to establish a new Hebei Province Microchannel Continuous Pharmaceutical Technology Innovation Center (河北省微通道連續製藥技術創新中心) this year, which will help improve the level of research and development of the Group.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 3 September 2021

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.